Accretion Pharmaceuticals IPO GMP & Review: Apply or Avoid?

Accretion Pharmaceuticals IPO is all set to open for bidding on 14th May 2025. It is a bookbuilding IPO consisting of a fresh issue of 29.46 lakh shares worth ₹29.75 crores. The issue will be listed on NSE and SME on its tentative listing date, 21st May 2025. 

Accretion Pharmaceuticals IPO Details 

Accretion Pharmaceuticals IPO date is fixed between 14th May 2025 and 16th May 2025. The face value of Accretion Pharmaceuticals Limited shares stands at ₹10 per share, and the IPO price band is fixed between ₹96 to ₹101 per share. 

Kfin Technologies Limited is the registrar of Accretion Pharmaceuticals IPO and is responsible for managing the allotment process and initiating refunds. Check out the latest IPO details in the table below. 

Accretion Pharmaceuticals IPO Share Reservation

Accretion Pharmaceuticals IPO is a bookbuilding issue of 29.46 lakh shares worth ₹29.75 crore. Accretion Pharmaceuticals Limited shares will be listed on the NSE and SME. Furthermore, SEBI has specified the share reservation criteria for different investor categories. 

Accretion Pharmaceuticals IPO GMP Grey Market Premium

GMP is the gap between the price band of the issue and the price at which company shares are currently trading in the grey market. Do you want to get live updates on Accretion Pharmaceuticals IPO GMP? If yes, then you’ve reached the right spot. Check the table below to learn about the GMP trends.

As of 13th May 2025, Accretion Pharmaceuticals IPO GMP stands at ₹0 per share, which means the share will likely show a flat listing at ₹101 (101+0) on its tentative listing date, 21st May 2025.

GMP data is subject to change based on market trends and sentiments. You should check the live GMP status before applying for the Accretion Pharmaceuticals IPO. Stay informed with Univest to know about real-time insights on IPOs and their GMP trends. 

Accretion Pharmaceuticals IPO Review

Check out the detailed Accretion Pharmaceuticals IPO review for a thorough understanding of its potential to report listing gains on 21st May 2025. The Accretion Pharmaceuticals IPO review below will help you invest effectively to avoid significant losses. Explore more to make informed investment decisions on this IPO. 

Financial Health

Assess a company’s financial performance to know about its ability to sustain a competitive edge. Thus, it is essential to understand the growth margins and declines of the business financials before applying for the Accretion Pharmaceuticals IPO.

Accretion Pharmaceuticals Limited’s revenue rose 14.93% from ₹29.53 crores in March 2023 to ₹33.94 crores in March 2024. Moreover, the company’s PAT increased by 3,780.00% from ₹0.10 crores to ₹3.88 crores. 

Accretion Pharmaceuticals Limited has shown consistent revenue growth, indicating that the company is financially stable. Moreover, the brokers, investors, and RAs have a positive outlook for Accretion Pharmaceuticals IPO for its tentative listing day, which is 21st May 2025.  

Technical Analysis

A number of technical indicators are available to assess a company’s potential to deliver returns. Use the parameters mentioned below to analyse the technicals of Accretion Pharmaceuticals IPO.

The PE ratio of Accretion Pharmaceuticals Limited shares is 21.29, and its Earnings Per Share (EPS) stands at 4.74. The Accretion Pharmaceuticals IPO can potentially deliver gains on its tentative listing date, 21st May 2025. 

Accretion Pharmaceuticals Limited Peer Comparison

Note: The data, as mentioned above, is taken from authentic sources and highlights pre-issue information. The PE ratio and EPS of Accretion Pharmaceuticals Limited are subject to change after the IPO. Explore the table below to get post-issue updates on these two metrics. 

Accretion Pharmaceuticals IPO Subscription Status

Accretion Pharmaceuticals IPO is now open for bidding on 14th May 2025. The subscription status for this IPO is yet to be announced. Stay informed on this passage to check the live Accretion Pharmaceuticals IPO Subscription Status. 

About Accretion Pharmaceuticals Limited

Accretion Pharmaceuticals Limited was incorporated in 2012, manufacturing and selling tablets, capsules, and other healthcare products. It also offers contract manufacturing services and markets other tablets such as Oral Liquids, External Preparations, and Oral Powder. Accretion Pharmaceuticals Limited holds ISO 9001:2015, ISO 14001:2015, and ISO 22000:2005 certifications. Here are the major competitive strengths of Accretion Pharmaceuticals Limited. 

• Experienced Promoters and Management Team.
• Long-standing relationship with clients and suppliers.
• Focus on providing quality products.
• Management has built a supply chain and customer relations, creating goodwill and trust.

Accretion Pharmaceuticals Limited Financials

The company’s financial analysis is essential before applying for the Accretion Pharmaceuticals IPO. Look at the table to learn about Accretion Pharmaceuticals Limited’s financials. 

Explanation

Accretion Pharmaceuticals Limited’s revenue rose 14.93% from ₹29.53 crores in March 2023 to ₹33.94 crores in March 2024. Moreover, the company’s PAT increased by 3,780.00% from ₹0.10 crores to ₹3.88 crores. 

Accretion Pharmaceuticals IPO Bidding Requirements

Accretion Pharmaceuticals IPO has reserved lot sizes to be applied by different investor categories. Look at the table below to know about the requirements to be fulfilled for applying for this IPO. 

Accretion Pharmaceuticals IPO Promoter Holdings

Have a look at the table below to check the holdings of Accretion Pharmaceuticals Limited’s promoters: Mr. Mayur Popatlal, Mr. Harshad Nanubhai Rathod, Mr. Vivek Ashok Kumar Patel, and Mr. Hardik Mukundbhai Prajapati.

Note: Promoter Holdings’ value is to be calculated using Equity dilution, which represents the gap between shareholdings before and after the Issue. 

Aim of Accretion Pharmaceuticals IPO

The primary aim of the Accretion Pharmaceuticals IPO is to raise ₹29.75 crores. On the other hand, Accretion Pharmaceuticals Limited has decided to utilise these funds in different practices. Explore some of the secondary objectives for the Accretion Pharmaceuticals IPO.

• To meet capital expenditure on machinery and equipment.
• To meet general corporate purposes. 
• To meet the repayment of certain borrowings availed by the company.
• To meet the working capital requirements of the company. 

Should I Invest in Accretion Pharmaceuticals IPO?

“Accretion Pharmaceuticals Limited is engaged in the marketing and manufacturing of pharma products. It is largely operating on a B2B model. Spurt in its bottom lines from FY24 raise eyebrows and concern over its sustainability. It does contract manufacturing business that has large volume but less margins. Based on its financial data, the issue appears aggressively priced. Well-informed investors may park funds for long term.” ~ Dilip Davda (Editor at Chittorgarh Infotech Private Limited)

Explore the pros and cons of Accretion Pharmaceuticals IPO to know whether you should apply or avoid the issue. These pros and cons might help you know about the IPO’s efficiency in delivering profits in the coming decades. 

Pros of Accretion Pharmaceuticals IPO

• Experienced Promoters and Management.
• Delivering Quality Products.

Cons of Accretion Pharmaceuticals IPO

• Low Employee Base.
• Less Margins.

How to Apply for Accretion Pharmaceuticals IPO?

Check the steps mentioned below to apply for the Accretion Pharmaceuticals IPO. 

• Step 1: Conduct thorough research on Accretion Pharmaceuticals IPO GMP, subscription status, issue size, lot size, and other details. 
• Step 2: Open a demat account on Univest to learn about real-time insights on GMP and subscription status. You can also use your previous demat account by navigating to the IPO section. 
• Step 3: Make a bid for one lot of 1,200 shares worth ₹1,21,200 of the Accretion Pharmaceuticals IPO.   
• Step 4: You will receive a mandate request after making a bid. Approve the request to proceed further.    

Note: You can apply for the Accretion Pharmaceuticals IPO from more than one demat account to increase your allotment chances. 

How to Check Accretion Pharmaceuticals IPO Allotment Status?

You can check for the Accretion Pharmaceuticals IPO allotment in different ways. These include NSE and the registrar portal. Look at the steps mentioned below to check your allotment status online.

Check On NSE

• Visit the NSE Official Website.
• Navigate to the IPO Allotment Section. 
• Select Equity as the issue type. 
• Choose the Accretion Pharmaceuticals IPO.  
• Choose whether to proceed with the PAN number or the application number.
• Submit your details to get the allotment status online. 

Check On the Registrar Portal

• Visit the registrar portal. 
• Click on the allotment option.
• Fill in the required details.
• Click on the submit button to know your Accretion Pharmaceuticals IPO allotment status.

Let’s Wrap

Accretion Pharmaceuticals IPO is a bookbuilding issue of 29.46 lakh shares worth ₹29.75 crores. The shares of Accretion Pharmaceuticals Limited will be listed on NSE and SME on its tentative listing date of 21st May 2025. Researching Accretion Pharmaceuticals IPO GMP and reviews is highly suggested to book your ideal profitability. Brokers and investors have highlighted their pros and cons, so one must analyse them and decide accordingly.

Open a demat account on Univest now to initiate your investment journey!

FAQs on Accretion Pharmaceuticals IPO

How is Accretion Pharmaceuticals IPO?

Ans. Currently, on 13th May 2025, Accretion Pharmaceuticals IPO GMP (Grey Market Premium) stands at ₹0 (0.00 % up). It indicates that the estimated listing price could be ₹101 per share. It is entirely a fresh issue of 29.46 lakh shares worth ₹29.75 crore. The IPO issue price is set between ₹96 to ₹101 per share, and the face value of each share is ₹10. 

What is Accretion Pharmaceuticals IPO price?

Ans. The Accretion Pharmaceuticals IPO price band is set between ₹96 and ₹101 per share. Retail investors can apply for a minimum and maximum of 1 lot consisting of 1,200 shares worth ₹1,21,200. Moreover, HNIs are required to bid for a minimum of 2 lots (2,400 shares) worth ₹2,42,400. 

Is Accretion Pharmaceuticals IPO good?

Ans. During FY23- 24, Accretion Pharmaceuticals Limited’s revenue rose 14.93% from ₹29.53 crores in March 2023 to ₹33.94 crores in March 2024. Moreover, the company’s PAT increased by 3,780.00% from ₹0.10 crores to ₹3.88 crores.  However, industry experts suggest applying for this IPO with a long-term perspective.

Who is the registrar of the Accretion Pharmaceuticals IPO?

Ans. Kfin Technologies Limited is the registrar of Accretion Pharmaceuticals IPO, awaiting to manage the IPO allotment procedure and refund initiation. For any queries regarding Accretion Pharmaceuticals IPO allotment and refund, you can contact Kfin Techologies Limited at reachus@kfintech.com or 04067162222, 04079611000.

What is the issue size of the Accretion Pharmaceuticals IPO? 

Ans. Accretion Pharmaceuticals IPO is a bookbuilding IPO for 29.46 lakh shares worth ₹29.75 crore. It is entirely a fresh issue. Moreover, the IPO is set to open on 14th May 2025 and will be closed on 16th May 2025. 

Disclaimer: The above information is compiled from authentic sources and is just for informational purposes. To have detailed information about the Accretion Pharmaceuticals IPO, download the Accretion Pharmaceuticals IPO RHP and Accretion Pharmaceuticals IPO DRHP. Conduct your own research before investing in IPOs to avoid significant losses. You can also consult your financial advisor.

Read Our Articles on the Best Stocks

Best Gold Stocks India

Green Energy Penny Stocks

Best Cement Stocks To Invest in India

What is Earnings Per Share EPS? 

Top Multibagger Penny Stocks For 2025 |  Potential Picks

Fundamentally Strong Stocks on NSE in 2025

Debt-Free Penny Stocks in India 2025

Best Realty Stocks In India 2025

Debt Free Penny Stocks Below 1 Rupee

Also Explore

Explore Current and Previous IPOs

Univest Screeners

Explore Webstories on Univest 

1. Best Time To Buy Dividend Stocks

2. How RBI Policies Affect Dividend Stocks

3. Can Dividend Stocks Beat Inflation

4. What Is The Dividend Aristocrat List

5. Which Indian Psus Offer The Best Dividends

6. Large Cap Vs Small Cap Dividend Stocks

Disclaimer: This is for general information and education purposes only. The Securities quoted (if any) are for illustration only and are not recommendatory. Past performance does not guarantee any future returns. Investments in the securities market are subject to market risks. Read all the related documents carefully before investing.